STARD13 and lung carcinoma: Although DLC2 and DLC3 expression was also reduced in both forms of lung cancer, the fold-reduction of DLC1 in each tumor type was more than twice that of DLC2 or DLC3. Because the expression of DLC1 in the non-tumor tissue was so much higher than that of DLC2 and DLC3, the magnitude of the reduction in the number of DLC1 RNA molecules in the tumors was far larger than that of the reduction in the number of DLC2 and DLC3 RNA molecules.